We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is pursuing two primary approaches to fully realize the transformative potential of CRISPR/Cas9 in vivo programs that use intravenously administered CRISPR as the therapy and ex vivo programs that use CRISPR to create the therapy by using engineered human cells.'
- Recent NTLA Stock Price: $62.53
- Yearly Gain for NTLA stock: -57.22%
- Market Cap for NTLA stock: $4.82B
- P/E Ratio for NTLA stock: -11.85
Will NTLA's stock price go up? Is there an accurate NTLA stock forecast available?
TipRanks.com reports that Intellia Therapeutics currently has 15 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $110.46. The target pricing ranges from a high NTLA forecast of $163.00 down to a low forecast of $50.00. Intellia Therapeutics (NTLA)’s last closing stock price was $62.53 which would put the average price target at 76.65% upside.
In addition, Barchart.com has a hold rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on NTLA stock.
Other analysts covering NTLA include:
- Mani Foroohar of SVB Securities issued a Buy rating with the price target of $ 158 on 2 days ago
- Geulah Livshits of Chardan Capital issued a Buy rating with the price target of $ 146 on 5 days ago
- Steven Seedhouse of Raymond James issued a Buy rating with the price target of $ 127 on 5 days ago
- Swapnil Malekar of Piper Sandler issued a Buy rating with the price target of $ 163 on 5 days ago
If you are wondering if NTLA is a good stock to buy, here are 3rd party ratings for NTLA stock:
- TipRanks.com: Moderate Buy
- TradingView.com: n/a
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: hold
- Zacks.com: Hold, Top 30% (75 out of 251)
What is the sentiment on the street regarding Intellia Therapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for NTLA stock: Very Bullish
- Blogger Consensus for NTLA stock: Bullish
- Media Buzz for NTLA stock: Very High
- Insider Signal for NTLA stock: n/a
- Investor Sentiment for NTLA stock: Neutral
- Hedge Fund signal for NTLA stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on NTLA stock including scouring the social networks like NTLA StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for NTLA stock chart >>
Summary: The Beauty Health Company is a beauty health company. Its flagship brand HydraFacial is a non-invasive and approachable beauty health platform and ecosystem with a powerful community of estheticians, consumers and partners, bridging medical and consumer retail to democratize and personalize skin care solutions for the masses. The Beauty Health Company, formerly known as Vesper Healthcare Acquisition Corp., is based in CHICAGO, Utah.
- Recent SKIN Stock Price: $11.8
- Yearly Gain for SKIN stock: -52.38%
- Market Cap for SKIN stock: $1.84B
- P/E Ratio for SKIN stock: -6.238
Will SKIN's stock price go up? Is there an accurate SKIN stock forecast available?
TipRanks.com reports that Beauty Health currently has 8 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $22.63. The target pricing ranges from a high SKIN forecast of $30.00 down to a low forecast of $20.00. Beauty Health (SKIN)’s last closing stock price was $11.8 which would put the average price target at 91.78% upside.
In addition, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on SKIN stock.
Other analysts covering SKIN include:
- Linda Bolton Weiser of D.A. Davidson issued a Buy rating with the price target of $ 30 on 5 days ago
- Korinne Wolfmeyer of Piper Sandler issued a Buy rating with the price target of $ 23 on 5 days ago
- Allen Gong of J.P. Morgan issued a Buy rating with the price target of $ 22 on 6 days ago
- Jonathan Block of Stifel Nicolaus issued a Buy rating with the price target of $ 20 on 3 weeks ago
If you are wondering if SKIN is a good stock to buy, here are 3rd party ratings for SKIN stock:
- TipRanks.com: Strong Buy
- TradingView.com: n/a
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 43% (143 out of 251)
What is the sentiment on the street regarding Beauty Health? (Current ratings compiled by TipRanks.com)
- News Sentiment for SKIN stock: Very Bullish
- Blogger Consensus for SKIN stock: Bullish
- Media Buzz for SKIN stock: Very High
- Insider Signal for SKIN stock: n/a
- Investor Sentiment for SKIN stock: Negative
- Hedge Fund signal for SKIN stock: Neutral
The stock market is extremely volatile, and you need to do your own research on SKIN stock including scouring the social networks like SKIN StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for SKIN stock chart >>
Summary: Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care.
- Recent EW Stock Price: $87.19
- Yearly Gain for EW stock: -20.88%
- Market Cap for EW stock: $55.07B
- P/E Ratio for EW stock: 40.393
Will EW's stock price go up? Is there an accurate EW stock forecast available?
TipRanks.com reports that Edwards Lifesciences currently has 16 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $116.13. The target pricing ranges from a high EW forecast of $128.00 down to a low forecast of $94.00. Edwards Lifesciences (EW)’s last closing stock price was $87.19 which would put the average price target at 33.19% upside.
In addition, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on EW stock.
Other analysts covering EW include:
- Josh Jennings of Cowen & Co. issued a Buy rating with the price target of $ 125 on 2 days ago
- Shagun Singh Chadha of RBC Capital issued a Buy rating with the price target of $ 128 on 1 month ago
- Lorenzo Biasio of Credit Suisse issued a Hold rating with the price target of $ 94 on 1 month ago
If you are wondering if EW is a good stock to buy, here are 3rd party ratings for EW stock:
- TipRanks.com: Strong Buy
- TradingView.com: n/a
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 38% (155 out of 251)
What is the sentiment on the street regarding Edwards Lifesciences? (Current ratings compiled by TipRanks.com)
- News Sentiment for EW stock: Very Bullish
- Blogger Consensus for EW stock: Bullish
- Media Buzz for EW stock: High
- Insider Signal for EW stock: Negative
- Investor Sentiment for EW stock: Neutral
- Hedge Fund signal for EW stock: Neutral
The stock market is extremely volatile, and you need to do your own research on EW stock including scouring the social networks like EW StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for EW stock chart >>
Summary: Alcon Inc. researches, develops, manufactures, distributes, and sells a full suite of eye care products. Alcon operates within two segments, Surgical and Vision Care. The Surgical segment is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery, and includes implantables, consumables, and surgical equipment required for these procedures. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, and a comprehensive portfolio of ocular health products, including products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers.
- Recent ALC Stock Price: $65.23
- Yearly Gain for ALC stock: -20.39%
- Market Cap for ALC stock: $33.23B
- P/E Ratio for ALC stock: 71.812
Will ALC's stock price go up? Is there an accurate ALC stock forecast available?
TipRanks.com reports that Alcon currently has 12 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $79.71. The target pricing ranges from a high ALC forecast of $89.21 down to a low forecast of $66.39. Alcon (ALC)’s last closing stock price was $65.23 which would put the average price target at 22.15% upside.
In addition, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ALC stock.
Other analysts covering ALC include:
- Delphine Le Louet of Societe Generale issued a Hold rating with the price target of $ 77.48 on 1 week ago
- Beatrice Allen of Berenberg Bank issued a Buy rating with the price target of $ 89.21 on 1 week ago
- Christoph Gretler of Credit Suisse issued a Buy rating with the price target of $ 87.13 on 1 week ago
- David Saxon of Needham issued a Buy rating with the price target of $ 85 on 4 weeks ago
If you are wondering if ALC is a good stock to buy, here are 3rd party ratings for ALC stock:
- TipRanks.com: Moderate Buy
- TradingView.com: n/a
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Sell, Bottom 38% (155 out of 251)
What is the sentiment on the street regarding Alcon? (Current ratings compiled by TipRanks.com)
- News Sentiment for ALC stock: Very Bullish
- Blogger Consensus for ALC stock: Bullish
- Media Buzz for ALC stock: Medium
- Insider Signal for ALC stock: n/a
- Investor Sentiment for ALC stock: Negative
- Hedge Fund signal for ALC stock: Negative
The stock market is extremely volatile, and you need to do your own research on ALC stock including scouring the social networks like ALC StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ALC stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
==============================================================================
